A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract
Francisco M. Marty(Brigham and Women's Hospital), Sanjeet Dadwal(City Of Hope National Medical Center), Kathleen M. Mullane(Karolinska University Hospital), Shmuel Shoham(Office of Infectious Diseases), Michael Boeckh, Jason W. Chien(Gilead Sciences (United States)), Alpana Waghmare(University of Washington), Anne Bergeron(Délégation Paris 7), Dong‐Gun Lee(Korea University), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Danielle Porter(Gilead Sciences (United States)), Catherine B. Small(Cornell University), Per Ljungman(Leiden University Medical Center), Yae‐Jean Kim, Élodie Blanchard(Centre Hospitalier Universitaire de Bordeaux), Ying Guo(Gilead Sciences (United States)), Robert Jordan(Gilead Sciences (United States)), Matt McKevitt(Gilead Sciences (United States)), Polina German(Gilead Sciences (United States)), Timothy R. Watkins(Gilead Sciences (United States)), Hans H. Hirsch(University of Basel)
Cited by 76
Related Papers
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
|Biology of Blood and Marrow Transplantation|2009|1.8k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863